- Date 12 Feb 2019
- Time 10:00 - 13:00
- Address The Bradfield Centre Milton Road CB4 0GF
As the adoption of Risk Based Monitoring (RBM) continues to grow across the clinical development industry, its impact is clear. RBM improves the quality, safety and efﬁciency of clinical trial management. While benefits are apparent, the industry is struggling to implement with confidence and gain the achievable benefits.
During this executive roundtable, Advanced Clinical and TRI will share the latest industry insights on what RBM means for your trials, practical guidance on how to implement and how to ensure compliance with ICH E6 (R2) when working with a CRO partner. The event will be run by a team of experts from Advanced Clinical and TRI and will be a great way to both accelerate your implementation of RBM and network with like-minded industry professionals.
Space is limited. Complimentary lunch will be served. Free parking is available.
Attend this event if you:
Understand what RBM is, but are looking for a practical implementation approach
Have started implementation, but are struggling to finish
Have implemented RBM, and are now looking for tools and processes to maximize the value
Are outsourcing your trials, and want to understand how RBM works under an outsourced model
Want to share and learn with other RBM professionals
Graham Belgrave, Senior Vice President, European Operations
Duncan Hall, CEO
Tammy Finnigan, COO
Triumph Research Intelligence (TRI) is a leading provider of Risk-Based Monitoring (RBM) solutions for clinical trials. It is based in Cambridge, UK, and Raleigh, North Carolina in the United States. Over 10% of failed NDA submissions are due to data quality and cost the industry hundreds of millions of dollars each year. TRI was founded in 2011 by CEO Duncan Hall to directly address this issue. TRIs products, solutions and services are designed to optimize clinical trial quality by improving data reliability and at the same time increase patient safety and operational efficiency.